Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00522990 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
A Phase 1 study, sponsored by Astex Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00522990: Clinical Trial Phase 1 study, sponsored by Astex Pharmaceuticals.
NCT00522990 is a Phase 1 study that was terminated before completion, run by Astex Pharmaceuticals. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00522990, a Phase 1 study, was terminated before completion, sponsored by Astex Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of AT9283 that can be given to patients who have ALL, AML, CML, high-risk myelodysplastic syndromes, or myelofibrosis with myeloid metaplasia. Researchers want to perform pharmacokinetic (PK) testing on blood to find out how quickly the study drug leaves the body and how the body breaks down the drug. The safety and effectiveness of this drug will also be studied.
Interventions
- DRUG AT9283
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Why NCT00522990 stopped before completion
NCT00522990 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 1 intervention - of which AT9283 is the first listed.
NCT00522990 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00522990 about?
NCT00522990 is a clinical study titled "Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias". The goal of this clinical research study is to find the highest tolerable dose of AT9283 that can be given to patients who have ALL, AML, CML, high-risk myelodysplastic syndromes, or myelofibrosis with myeloid metaplasia. Researchers want to perform pharmacokinetic (PK) testing on blood to find out ...
What is the current status of trial NCT00522990?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2006-09. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00522990?
The interventions under investigation include: AT9283 (DRUG).
Who is sponsoring clinical trial NCT00522990?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00522990's enrollment target sits among peer trials
48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia